Metformin slows down aging and extends life span of female SHR mice

被引:276
作者
Anisimov, Vladimir N. [1 ]
Berstein, Lev M. [1 ]
Egormin, Peter A. [1 ]
Piskunova, Tatiana S. [1 ]
Popovich, Irina G. [1 ]
Zabezhinski, Mark A. [1 ]
Tyndyk, Margarita L. [1 ]
Yurova, Maria V. [1 ]
Kovalenko, Irina G. [1 ]
Poroshina, Tatiana E. [1 ]
Semenchenko, Anna V. [1 ]
机构
[1] NN Petrov Oncol Res Inst, Dept Carcinogenesis & Oncogerontol, St Petersburg 197758, Russia
基金
俄罗斯基础研究基金会;
关键词
metformin; biomarkers of aging; life extension; spontaneous carcinogenesis; mice;
D O I
10.4161/cc.7.17.6625
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Studies in mammals have led to the suggestion that hyperglycemia and hyperinsulinemia are important factors both in aging and in the development of cancer. It is possible that the life-prolonging effects of calorie restriction are due to decreasing IGF-1 levels. A search of pharmacological modulators of insulin/IGF-1 signaling pathway (which resemble effects of life span extending mutations or calorie restriction) could be a perspective direction in regulation of longevity. Antidiabetic biguanides are most promising among them. Here we show the chronic treatment of female outbred SHR mice with metformin (100 mg/kg in drinking water) slightly modified the food consumption but decreased the body weight after the age of 20 months, slowed down the age-related switch-off of estrous function, increased mean life span by 37.8%, mean life span of last 10% survivors by 20.8%, and maximum life span by 2.8 months (+ 10.3%) in comparison with control mice. On the other side, treatment with metformin failed influence blood estradiol concentration and spontaneous tumor incidence in female SHR mice. Thus, antidiabetic biguanide metformin dramatically extends life span, even without cancer prevention in this model.
引用
收藏
页码:2769 / 2773
页数:5
相关论文
共 46 条
[1]  
Anisimov V.N., 1987, CARCINOGENESIS AGING, V2
[2]  
Anisimov Vladimir N, 2007, Methods Mol Biol, V371, P227
[3]   Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice [J].
Anisimov, VN ;
Berstein, LM ;
Egormin, PA ;
Piskunova, TS ;
Popovich, IG ;
Zabezhinski, MA ;
Kovalenko, IG ;
Poroshina, TE ;
Semenchenko, AV ;
Provinciali, M ;
Re, F ;
Franceschi, C .
EXPERIMENTAL GERONTOLOGY, 2005, 40 (8-9) :685-693
[4]   Insulin/IGF-1 signaling pathway driving aging and cancer as a target for pharmacological intervention [J].
Anisimov, VN .
EXPERIMENTAL GERONTOLOGY, 2003, 38 (10) :1041-1049
[5]   Insulin and longevity: antidiabetic biguanides as geroprotectors [J].
Anisimov, VN ;
Semenchenko, AV ;
Yashin, AI .
BIOGERONTOLOGY, 2003, 4 (05) :297-307
[6]  
Awartani Khalid A, 2002, J Obstet Gynaecol Can, V24, P393
[7]   Insulin-like growth factor 1 (IGF-1) and aging: controversies and new insights [J].
Bartke, A ;
Chandrashekar, V ;
Dominici, F ;
Turyn, D ;
Kinney, B ;
Steger, R ;
Kopchick, JJ .
BIOGERONTOLOGY, 2003, 4 (01) :1-8
[8]   Clinical usage of hypolipidemic and antidiabetic drugs in the prevention and treatment of cancer [J].
Berstein, LM .
CANCER LETTERS, 2005, 224 (02) :203-212
[9]   An anti-aging drug today: from senescence-promoting genes to anti-aging pill [J].
Blagosklonny, Mikhail V. .
DRUG DISCOVERY TODAY, 2007, 12 (5-6) :218-224
[10]   Aging and immortality - Quasi-programmed senescence and its pharmacologic inhibition [J].
Blagosklonny, Mikhail V. .
CELL CYCLE, 2006, 5 (18) :2087-2102